A versatile drug delivery system targeting senescent cells
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Senescent cells accumulate in multiple aging‐associated diseases, and eliminating these cells has recently emerged as a promising therapeutic approach. Here, we take advantage of the high lysosomal β‐galactosidase activity of senescent cells to design a drug delivery system based on the encapsulation of drugs with galacto‐oligosaccharides. We show that gal‐encapsulated fluorophores are preferentially released within senescent cells in mice. In a model of chemotherapy‐induced senescence, gal‐encapsulated cytotoxic drugs target senescent tumor cells and improve tumor xenograft regression in combination with palbociclib. Moreover, in a model of pulmonary fibrosis in mice, gal‐encapsulated cytotoxics target senescent cells, reducing collagen deposition and restoring pulmonary function. Finally, gal‐encapsulation reduces the toxic side effects of the cytotoxic drugs. Drug delivery into senescent cells opens new diagnostic and therapeutic applications for senescence‐associated disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“One approach stems from the increase in lysosomal mass and senescence-associated β-galactosidase activity in many senescent cells, whereby galacto-oligosaccharide-coated nanoparticles and β-galactosidase-activated prodrugs appear to eliminate at least some of these cells92,93.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Nanoparticles containing either fluorophores or cytotoxic agents coated with galacto-oligosaccharides were found to preferentially deliver cytotoxic cargo to senescent cells because of the higher level of SA-β-gal activity in these cells218.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [218]
The cited source says what the claim attributes to it.
In the citing paper
“A senescence transcriptional signature could enable rapid detection of senescent cells, and multiple such gene sets have been described132–136,139.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [134]
The cited source says what the claim attributes to it.
In the citing paper
“Galacto-oligosaccharide encapsulated nanoparticles (GalNP) containing cytotoxic or senolytic drugs (Muñoz-Espín et al. 2018) and galactose-derived prodrugs display senolytic properties (González-Gualda et al. 2020; Guerrero et al. 2020)”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Muñoz-Espín et al. 2018
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Spatial omics has not yet been used extensively for senescence research but is in development132–136.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [134]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“0.10 (Trapnell et al, 2012), Bowtie 1.0.0 (Langmead et al, 2009) and Samtools 0.1.19.0 (Li et al, 2009); and transcripts assembly, abundances estimation, and differential expression were calculated with DESeq2 (Love et al, 2014).”
InfluentialThe Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 1×
“0.10 (Trapnell et al, 2012), Bowtie 1.0.0 (Langmead et al, 2009) and Samtools 0.1.19.0 (Li et al, 2009); and transcripts assembly, abundances estimation, and differential expression were calculated with DESeq2 (Love et al, 2014).”
MethodInfluentialUltrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849 · cited 1×
“0.10 (Trapnell et al, 2012), Bowtie 1.0.0 (Langmead et al, 2009) and Samtools 0.1.19.0 (Li et al, 2009); and transcripts assembly, abundances estimation, and differential expression were calculated with DESeq2 (Love et al, 2014).”
MethodInfluentialOrdered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism
Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., & Beck, J. S. (1992) · Nature · doi:10.1038/359710a0 · Cited by 16,275 · cited 4×
“For the synthesis of the mesoporous silica MCM-41 scaffolds (Kresge et al, 1992), N-cetyltrimethylammonium bromide (CTAB, Sigma, #H6269) was first dissolved in 480 ml of deionized water at 2.74 mM.”
BackgroundMethodInfluentialTrapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,116 · cited 1×
“0.10 (Trapnell et al, 2012), Bowtie 1.0.0 (Langmead et al, 2009) and Samtools 0.1.19.0 (Li et al, 2009); and transcripts assembly, abundances estimation, and differential expression were calculated with DESeq2 (Love et al, 2014).”
MethodInfluentialA biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · cited 1×
“In this regard, it is relevant to mention that macrophages are known to metabolize nanoparticles (Wilhelm et al, 2016) and can present SAbGal activity without actually being senescent (Hall et al, 2017).”
BackgroundNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 1×
“Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 10: e9355 | 2018 1 of 18 processes associated with chemotherapy, and extends longevity (Baker et al, 2016; Childs et al, 2016; Demaria et al, 2017).”
MethodInfluentialCellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
Self-citationThe Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 3×
“Importantly, senescent cells present vulnerabilities to particular small molecule inhibitors, known as “senolytics”, that trigger apoptosis preferentially in senescent cells (Zhu et al, 2015).”
Background
Cited by
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
Senolytic drugs: from discovery to translation
Kirkland, J. L., & Tchkonia, T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13141 · Cited by 1,227
Senescence and the SASP: many therapeutic avenues
Birch, J., & Gil, J. (2020) · Genes & Development · doi:10.1101/gad.343129.120 · Cited by 1,177
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,134
Self-citationExploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
A guide to assessing cellular senescence in vitro and in vivo
González‐Gualda, E., Baker, A. G., Fruk, L., & Muñoz‐Espín, D. (2021) · The FEBS Journal · doi:10.1111/febs.15570 · Cited by 645
Self-citationTargeting cellular senescence with senotherapeutics: senolytics and senomorphics
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D. (2023) · The FEBS Journal · doi:10.1111/febs.16350 · Cited by 621
Cellular senescence: a key therapeutic target in aging and diseases
Zhang, L., Pitcher, L. E., Yousefzadeh, M. J., Niedernhofer, L. J., Robbins, P. D., & Zhu, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158450 · Cited by 631
“For example, doxorubicin and navitoclax were encapsulated in NPs as payloads to generate senolytic nanoparticles GalNP(dox) and GalNP(nav) (109).”
BackgroundMethodSenescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508
“Melanoma (SK-MEL-103) (i) Elevated SA-β-galactosidase activities 1 μM for 7 days [32]”
BackgroundInfluentialStrategies for targeting senescent cells in human disease
Gasek, N. S., Kuchel, G. A., Kirkland, J. L., & Xu, M. (2021) · Nature Aging · doi:10.1038/s43587-021-00121-8 · Cited by 501
The ageing epigenome and its rejuvenation
Zhang, W., Qu, J., Liu, G.-H., & Belmonte, J. C. I. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0204-5 · Cited by 458
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
“518,519 FUTURE PERSPECTIVES BCL2 inhibitors: can venetoclax be bettered?”
Cai, Y., Zhou, H., Zhu, Y., Sun, Q., Ji, Y., Xue, A., Wang, Y., Chen, W., Yu, X., Wang, L., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0314-9 · Cited by 397
“[36] [37] [38] We treated these lung-injured mice with vehicle or SSK1 by intraperitoneal injection (Fig.”
MethodGuidelines for minimal information on cellular senescence experimentation in vivo
Ogrodnik, M., Carlos Acosta, J., Adams, P. D., d’Adda di Fagagna, F., Baker, D. J., Bishop, C. L., Chandra, T., Collado, M., Gil, J., Gorgoulis, V., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.059 · Cited by 376
Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span
Robbins, P. D., Jurk, D., Khosla, S., Kirkland, J. L., LeBrasseur, N. K., Miller, J. D., Passos, J. F., Pignolo, R. J., Tchkonia, T., & Niedernhofer, L. J. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-050120-105018 · Cited by 360
Mitochondrial dysfunction and cell senescence: deciphering a complex relationship
Chapman, J., Fielder, E., & Passos, J. F. (2019) · FEBS Letters · doi:10.1002/1873-3468.13498 · Cited by 325
Interconnections between Inflammageing and Immunosenescence during Ageing
Teissier, T., Boulanger, E., & Cox, L. S. (2022) · Cells · doi:10.3390/cells11030359 · Cited by 301
“Similar findings have been made with nanoparticles targeting senescent cells where senescent cell removal was possibly associated with reduced SASP [408].”
González‐Gualda, E., Pàez‐Ribes, M., Lozano‐Torres, B., Macias, D., Wilson, J. R., González‐López, C., Ou, H., Mirón‐Barroso, S., Zhang, Z., Lérida‐Viso, A., et al. (2020) · Aging Cell · doi:10.1111/acel.13142 · Cited by 303
Self-citationCellular senescence in development, regeneration and disease
Rhinn, M., Ritschka, B., & Keyes, W. M. (2019) · Development · doi:10.1242/dev.151837 · Cited by 279
“…osteoarthritis (Jeon et al., 2017), osteoporosis (Farr et al., 2017), atherosclerosis (Childs et al., 2016), Parkinson’s (Chinta et al., 2018), Alzheimer’s (Bussian et al., 2018; Musi et al., 2018) and others, whereas the selective deletion of p16INK4A-positive cells improves many disease symptoms.”
BackgroundTargeting senescent cells in translational medicine
Paez‐Ribes, M., González‐Gualda, E., Doherty, G. J., & Muñoz‐Espín, D. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201810234 · Cited by 293
Self-citationCellular Senescence in the Kidney
Docherty, M.-H., O’Sullivan, E. D., Bonventre, J. V., & Ferenbach, D. A. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018121251 · Cited by 291
Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy
Saleh, T., Bloukh, S., Carpenter, V. J., Alwohoush, E., Bakeer, J., Darwish, S., Azab, B., & Gewirtz, D. A. (2020) · Cancers · doi:10.3390/cancers12040822 · Cited by 290
Biosafety of mesoporous silica nanoparticles; towards clinical translation
Lérida-Viso, A., Estepa-Fernández, A., García-Fernández, A., Martí-Centelles, V., & Martínez-Máñez, R. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115049 · Cited by 279
Self-citationHe, Y., Zhang, X., Chang, J., Kim, H.-N., Zhang, P., Wang, Y., Khan, S., Liu, X., Zhang, X., Lv, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15838-0 · Cited by 280
Cellular senescence and SASP in tumor progression and therapeutic opportunities
Dong, Z., Luo, Y., Yuan, Z., Tian, Y., Jin, T., & Xu, F. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02096-7 · Cited by 259
“These nanoparticles release their encapsulated senolytics upon digestion by elevated SA-β-gal activity in senescent cells, effectively killing them [184].”
BackgroundSenolytic therapies for healthy longevity.
van Deursen, J. M. (2019) · Science · doi:10.1126/science.aaw1299 · Cited by 237
Amor, C., Fernández-Maestre, I., Chowdhury, S., Ho, Y.-J., Nadella, S., Graham, C., Carrasco, S. E., Nnuji-John, E., Feucht, J., Hinterleitner, C., et al. (2024) · Nature Aging · doi:10.1038/s43587-023-00560-5 · Cited by 228
“…uPAR-targeting CAR T cells on physiologically aged mice, we intravenously infused damage and decreased function of the immune system leads to the accumulation of senescent cells 4,5 , thereby generating a chronic pro-inflammatory milieu that leads to a range of age-related tissue pathologies 6–9 .”
BackgroundHan, Y., & Kim, S. Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00906-w · Cited by 201
Cellular senescence in cancer: from mechanisms to detection
Ou, H., Hoffmann, R., González‐López, C., Doherty, G. J., Korkola, J. E., & Muñoz‐Espín, D. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12807 · Cited by 190
Self-citationSenescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188
“This could be combined with senescent cell-specific delivery methods, such as the galactose-encapsulation of drugs that reduced thrombocytopenia after navitoclax application in an experimental setting.(191) Alternatively, the drugs could be applied periodically, with long offdrug periods.”
Saleh, T., Carpenter, V. J., Tyutyunyk‐Massey, L., Murray, G., Leverson, J. D., Souers, A. J., Alotaibi, M. R., Faber, A. C., Reed, J., Harada, H., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12761 · Cited by 190
Mesoporous silica nanoparticles for pulmonary drug delivery
García-Fernández, A., Sancenón, F., & Martínez-Máñez, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113953 · Cited by 183
Self-citationSenescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs
Kudlova, N., De Sanctis, J. B., & Hajduch, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084168 · Cited by 171
Obesity and type-2 diabetes as inducers of premature cellular senescence and ageing
Burton, D. G. A., & Faragher, R. G. A. (2018) · Biogerontology · doi:10.1007/s10522-018-9763-7 · Cited by 173
Galactose‐modified duocarmycin prodrugs as senolytics
Guerrero, A., Guiho, R., Herranz, N., Uren, A., Withers, D. J., Martínez‐Barbera, J. P., Tietze, L. F., & Gil, J. (2020) · Aging Cell · doi:10.1111/acel.13133 · Cited by 172
“Consequently, this GalNP can be used in combination with different cargos to either image or kill senescent cells (Munoz-Espin et al. 2018).”
Basu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171
Immunomodulation by anticancer cell cycle inhibitors
Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0300-y · Cited by 163
Cellular Senescence: From Mechanisms to Current Biomarkers and Senotherapies
Lucas, V., Cavadas, C., & Aveleira, C. A. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000622 · Cited by 160
Senescence and senotherapeutics: a new field in cancer therapy
Myrianthopoulos, V., Evangelou, K., Vasileiou, P. V. S., Cooks, T., Vassilakopoulos, T. P., Pangalis, G. A., Kouloukoussa, M., Kittas, C., Georgakilas, A. G., & Gorgoulis, V. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.006 · Cited by 160
Similarities and interplay between senescent cells and macrophages
Behmoaras, J., & Gil, J. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202010162 · Cited by 158
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
New Advances in In Vivo Applications of Gated Mesoporous Silica as Drug Delivery Nanocarriers
García‐Fernández, A., Aznar, E., Martínez‐Máñez, R., & Sancenón, F. (2019) · Small · doi:10.1002/smll.201902242 · Cited by 143
Self-citationWhen dormancy fuels tumour relapse
Santos-de-Frutos, K., & Djouder, N. (2021) · Communications Biology · doi:10.1038/s42003-021-02257-0 · Cited by 165
The costs and benefits of senotherapeutics for human health
Raffaele, M., & Vinciguerra, M. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00300-7 · Cited by 140
Lozano-Torres, B., Estepa-Fernández, A., Rovira, M., Orzáez, M., Serrano, M., Martínez-Máñez, R., & Sancenón, F. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0108-0 · Cited by 140
Self-citationSenescence and the tumor-immune landscape: Implications for cancer immunotherapy
Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 161
Poblocka, M., Bassey, A. L., Smith, V. M., Falcicchio, M., Manso, A. S., Althubiti, M., Sheng, X., Kyle, A., Barber, R., Frigerio, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99852-2 · Cited by 137
Targeting Cardiac Stem Cell Senescence to Treat Cardiac Aging and Disease
Cianflone, E., Torella, M., Biamonte, F., De Angelis, A., Urbanek, K., Costanzo, F. S., Rota, M., Ellison-Hughes, G. M., & Torella, D. (2020) · Cells · doi:10.3390/cells9061558 · Cited by 132
Targeting Senescent Cells for a Healthier Aging: Challenges and Opportunities
Song, S., Tchkonia, T., Jiang, J., Kirkland, J. L., & Sun, Y. (2020) · Advanced Science · doi:10.1002/advs.202002611 · Cited by 129
Emerging use of senolytics and senomorphics against aging and chronic diseases
Martel, J., Ojcius, D. M., Wu, C., Peng, H., Voisin, L., Perfettini, J., Ko, Y., & Young, J. D. (2020) · Medicinal Research Reviews · doi:10.1002/med.21702 · Cited by 127
Targeting senescent cells: approaches, opportunities, challenges
von Kobbe, C. (2019) · Aging · doi:10.18632/aging.102557 · Cited by 127
“To date there is no universal marker for senescence, and identification of senescent cells is based on the combined detection of two or more phenotypic aspects mentioned above, such as SA-β-Gal, p16Ink4a or p21WAF1 [10].”
BackgroundInfluentialSenolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124
New Dawn for Atherosclerosis: Vascular Endothelial Cell Senescence and Death
Bu, L.-L., Yuan, H., Xie, L., Guo, M.-H., Liao, D., & Zheng, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015160 · Cited by 145
Cellular senescence and cardiovascular diseases: moving to the “heart” of the problem
Evangelou, K., Vasileiou, P. V. S., Papaspyropoulos, A., Hazapis, O. G., Petty, R., Demaria, M., & Gorgoulis, V. G. (2022) · Physiological Reviews · doi:10.1152/physrev.00007.2022 · Cited by 135
Cellular senescence in lung cancer: Molecular mechanisms and therapeutic interventions
Jha, S. K., Rubis, G. D., Devkota, S. R., Zhang, Y., Adhikari, R., Jha, L. A., Bhattacharya, K., Mehndiratta, S., Gupta, G., Singh, S. K., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102315 · Cited by 151
Lau, L., Porciuncula, A., Yu, A., Iwakura, Y., & David, G. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00586-18 · Cited by 119
“cells with high levels of -galactosidase (59).”
Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic
Galiana, I., Lozano-Torres, B., Sancho, M., Alfonso, M., Bernardos, A., Bisbal, V., Serrano, M., Martínez-Máñez, R., & Orzáez, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.045 · Cited by 115
Self-citationRecent advances in the discovery of senolytics
Zhang, L., Pitcher, L. E., Prahalad, V., Niedernhofer, L. J., & Robbins, P. D. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111587 · Cited by 115
Lewinska, A., Adamczyk-Grochala, J., Bloniarz, D., Olszowka, J., Kulpa-Greszta, M., Litwinienko, G., Tomaszewska, A., Wnuk, M., & Pazik, R. (2020) · Redox Biology · doi:10.1016/j.redox.2019.101337 · Cited by 112
Cellular senescence in the lung across the age spectrum
Parikh, P., Wicher, S., Khandalavala, K., Pabelick, C. M., Britt, R. D., & Prakash, Y. S. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00424.2018 · Cited by 112
“This system improved pulmonary function in a bleomycin model of IPF, with a simultaneous reduction in toxicity (132).”
BackgroundThe bright and dark side of extracellular vesicles in the senescence-associated secretory phenotype
Wallis, R., Mizen, H., & Bishop, C. L. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111263 · Cited by 108
Detecting and targeting senescent cells using molecularly imprinted nanoparticles
Ekpenyong-Akiba, A. E., Canfarotta, F., Abd H., B., Poblocka, M., Casulleras, M., Castilla-Vallmanya, L., Kocsis-Fodor, G., Kelly, M. E., Janus, J., Althubiti, M., et al. (2019) · Nanoscale Horizons · doi:10.1039/c8nh00473k · Cited by 108
Targeting senescence as an anticancer therapy
Bousset, L., & Gil, J. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13312 · Cited by 105
Emerging senolytic agents derived from natural products
Li, W., Qin, L., Feng, R., Hu, G., Sun, H., He, Y., & Zhang, R. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.05.001 · Cited by 105
Targeting senescent cells for a healthier longevity: the roadmap for an era of global aging
Sun, Y., Li, Q., & Kirkland, J. L. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac030 · Cited by 105
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
Bonelli, M. A., Monica, S. L., Fumarola, C., & Alfieri, R. R. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113676 · Cited by 112
Strategies for late phase preclinical and early clinical trials of senolytics
Wissler Gerdes, E. O., Misra, A., Netto, J. M. E., Tchkonia, T., & Kirkland, J. L. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111591 · Cited by 103
EMT and Stemness—Key Players in Pancreatic Cancer Stem Cells
Rodríguez-Aznar, E., Wiesmüller, L., Sáinz, B., & Hermann, P. C. (2019) · Cancers · doi:10.3390/cancers11081136 · Cited by 108
Novel drug delivery systems and disease models for pulmonary fibrosis
Li, R., Jia, Y., Kong, X., Nie, Y., Deng, Y., & Liu, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.039 · Cited by 97
Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy
Triana-Martínez, F., Loza, M. I., & Domínguez, E. (2020) · Cells · doi:10.3390/cells9020346 · Cited by 95
Cellular senescence in cancer: clinical detection and prognostic implications
Domen, A., Deben, C., Verswyvel, J., Flieswasser, T., Prenen, H., Peeters, M., Lardon, F., & Wouters, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02555-3 · Cited by 94
López-Polo, V., Maus, M., Zacharioudakis, E., Lafarga, M., Attolini, C. S., Marques, F. M., Kovatcheva, M., Gavathiotis, E., & Serrano, M. (2024) · Nature Communications · doi:10.1038/s41467-024-51363-0 · Cited by 109
“We began by examining xenografts of human SK-MEL-103 cells grown in nude mice and treated with palbociclib, which ef fi ciently induces senescence in vivo 46 .”
MethodSelf-citationCellular senescence in skeletal disease: mechanisms and treatment
He, X., Hu, W., Zhang, Y., Chen, M., Ding, Y., Yang, H., He, F., Gu, Q., & Shi, Q. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00501-5 · Cited by 107
“This delivery system eliminates cells with high SA-β-gal activity (166).”
BackgroundDissecting primary and secondary senescence to enable new senotherapeutic strategies
Admasu, T. D., Rae, M. J., & Stolzing, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101412 · Cited by 102
Current senolytics: Mode of action, efficacy and limitations, and their future
Rad, A. N., & Grillari, J. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111888 · Cited by 83
Emerging insights in senescence: pathways from preclinical models to therapeutic innovations
Mansfield, L., Ramponi, V., Gupta, K., Stevenson, T., Mathew, A. B., Barinda, A. J., Herbstein, F., & Morsli, S. (2024) · npj Aging · doi:10.1038/s41514-024-00181-1 · Cited by 88
Short-term gain, long-term pain: the senescence life cycle and cancer
Chan, A. S. L., & Narita, M. (2019) · Genes & Development · doi:10.1101/gad.320937.118 · Cited by 80
“A more recent study also suggests that selective targeting of TIS cells using sugar-coated (thus sensitive to β-galactosidase) nanoparticles encapsulating cytotoxic drugs is beneficial in xenograft models (Muñoz-Espín et al. 2018).”
BackgroundLérida‐Viso, A., Estepa‐Fernández, A., Morellá‐Aucejo, Á., Lozano‐Torres, B., Alfonso, M., Blandez, J. F., Bisbal, V., Sepúlveda, P., García‐Fernández, A., Orzáez, M., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106356 · Cited by 87
Self-citationLiu, B., Peng, Z., Zhang, H., Zhang, N., Liu, Z., Xia, Z., Huang, S., Luo, P., & Cheng, Q. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02284-z · Cited by 105
“…high lysosomal β-galactosidase activity in senescent cells has been exploited to design delivery systems using galactooligosaccharide-coated drugs [364–366]; the lipofuscin accumulation in senescent cells has been utilized to develop micelle nanocarriers that bind to lipofuscin [367], allowing…”
Senescent cells as promising targets to tackle age-related diseases
Prašnikar, E., Borišek, J., & Perdih, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101251 · Cited by 73
Aging, Cell Senescence, the Pathogenesis and Targeted Therapies of Osteoarthritis
Zhang, X., He, S., Liang, X., Li, W., Li, T.-F., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.728100 · Cited by 88
The senescence journey in cancer immunoediting
Zingoni, A., Antonangeli, F., Sozzani, S., Santoni, A., Cippitelli, M., & Soriani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01973-5 · Cited by 84
“Interest-ingly, new nanotechnologies settled on the employment of galactose-modified nanoparticles have been recently proposed to increase the specificity of drug delivery into senescent cells [197, 198].”
BackgroundMalavolta, M., Giacconi, R., Brunetti, D., Provinciali, M., & Maggi, F. (2020) · Cells · doi:10.3390/cells9040909 · Cited by 72
The stromal microenvironment and ovarian aging: mechanisms and therapeutic opportunities
Shen, L., Liu, J., Luo, A., & Wang, S. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01300-4 · Cited by 96
“This gal-encapsulated biomaterial has been shown to reduce chemotherapy-induced cellular senescence and lung fibrosis in mice [188].”
BackgroundEndothelial Senescence: A New Age in Pulmonary Hypertension
Culley, M. K., & Chan, S. Y. (2022) · Circulation Research · doi:10.1161/circresaha.121.319815 · Cited by 75
Lozano‐Torres, B., Blandez, J. F., Galiana, I., García‐Fernández, A., Alfonso, M., Marcos, M. D., Orzáez, M., Sancenón, F., & Martínez‐Máñez, R. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004142 · Cited by 73
Self-citationPro- and anti-tumorigenic functions of the senescence-associated secretory phenotype
Lau, L., & David, G. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1565658 · Cited by 70
“More recent senolytics include drug delivery systems that selectively target senescent cells, such as GalNP [86].”
BackgroundGarcía‐Fernández, A., Sancho, M., Bisbal, V., Amorós, P., Marcos, M. D., Orzáez, M., Sancenón, F., & Martínez‐Máñez, R. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.010 · Cited by 75
Self-citationTherapeutic targeting of senescent cells in the CNS
Riessland, M., Ximerakis, M., Jarjour, A. A., Zhang, B., & Orr, M. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01033-z · Cited by 77
“Additionally, to selectively target senescent cells, researchers leveraged the elevated activity of the lysosomal β-galactosidase that is common in senescent cells, developing a drug delivery system based on encapsulating drugs with galacto ‐ oligosaccharides 114,115 .”
Towards precision medicine using biochemically triggered cleavable conjugation
Parshad, B., Arora, S., Singh, B., Pan, Y., Tang, J., Hu, Z., & Patra, H. K. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01491-5 · Cited by 72
“Moreover,ithasalsobeenfoundthatnanoparticlesfunctionalizedwith galactose moiety preferentially release their payload in senescent cells 66,67 .”
Senescence in chronic wounds and potential targeted therapies
Wei, X., Li, M., Zheng, Z., Ma, J., Gao, Y., Chen, L., Peng, Y., Yu, S., & Yang, L. (2022) · Burns & Trauma · doi:10.1093/burnst/tkab045 · Cited by 72
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 80
“This method has been tested in models of chemotherapy-induced senescence [370, 371].”
MethodKhalil, R., Diab‐Assaf, M., & Lemaître, J.-M. (2023) · Cells · doi:10.3390/cells12060915 · Cited by 73
The controversial role of senescence-associated secretory phenotype (SASP) in cancer therapy
Cao, L., Li, K., Li, Q., Tong, Q., Wang, Y., & Huang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02475-8 · Cited by 90
cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis
Wang, L., Jin, H., Jochems, F., Wang, S., Lieftink, C., Martinez, I. M., Conti, G. D., Edwards, F., de Oliveira, R. L., Schepers, A. G., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00462-2 · Cited by 78
Mbara, K. C., Devnarain, N., & Owira, P. M. O. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-022-00444-w · Cited by 47
Cellular Senescence in Human Skin Aging: Leveraging Senotherapeutics
Wyles, S. P., CARRUTHERS, J. D. A., Dashti, P., Yu, G., Yap, J. Q., Gingery, A., Tchkonia, T., & Kirkland, J. L. (2023) · Gerontology · doi:10.1159/000534756 · Cited by 71
COPI vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cells
McHugh, D., Sun, B., Gutierrez-Muñoz, C., Hernández-González, F., Mellone, M., Guiho, R., Duran, I., Pombo, J., Pietrocola, F., Birch, J., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01287-6 · Cited by 59
Self-citationSenolysis Enabled by Senescent Cell‐Sensitive Bioorthogonal Tetrazine Ligation
Chang, M., Dong, Y., Xu, H., Cruickshank‐Taylor, A. B., Kozora, J. S., Behpour, B., & Wang, W. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202315425 · Cited by 63
Metadata
- Authors
- Muñoz‐Espín, D., Rovira, M., Galiana, I., Giménez, C., Lozano‐Torres, B., Paez‐Ribes, M., Llanos, S., Chaib, S., Muñoz‐Martín, M., Ucero, A. C., Garaulet, G., Mulero, F., Dann, S. G., VanArsdale, T., Shields, D. J., Bernardos, A., Murguía, J. R., Martínez‐Máñez, R., & Serrano, M.
- Affiliations
- University of Cambridge (GB)
- Spanish National Cancer Research Centre (ES)
- Universitat de València (ES)
- Pfizer (United States) (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Muñoz‐Espín, Daniel
- Serrano, Manuel
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2018-07-16
- Volume
- 10
- Issue
- 9
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC6127887
- OpenAlex
- W2884253843
- Cited by
- 339
- References
- 64
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 52 · 2023: 45 · 2022: 48 · 2021: 28 · 2020: 52 · 2019: 31 · 2018: 2
- FWCI
- 19.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- RiuNet (Universitat Politècnica de València) (submittedVersion, cc-by-nc-nd)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Secretaría de Estado de Investigación, Desarrollo e Innovación (MAT2015‐64139‐C4‐1‐R)
- H2020 European Research Council
- Instituto de Salud Carlos III (DTS16/00205)
- European Regional Development Fund
- European Social Fund
- Institut Ruđer Bošković
- Fundación Botín
- Banco Santander
- “la Caixa” Foundation
- Cancer Research UK (C9685‐A25177, RG86786)
- Generalitat Valenciana (PROMETEOII/2014/047)
- Pfizer
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- senolytics, senescent cells, drug delivery systems, galactooligosaccharides, lysosomal beta-galactosidase, chemotherapy-induced senescence, palbociclib, age-related diseases
- MeSH terms
- Animals, beta-Galactosidase, Cell Survival, Cytotoxins, Disease Models, Animal, Drug Compounding, Fluorescent Dyes, Galactose, Lysosomes, Neoplasm Transplantation, Neoplasms, Oligosaccharides, Piperazines, Pyridines, Staining and Labeling, Drug Delivery Systems, Cellular Senescence, Mice, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.